- Home
- RNAC vs MOLN Comparison
RNAC vs MOLN Comparison
Compare RNAC & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNAC | MOLN |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.3M | 144.0M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RNAC | MOLN |
|---|---|---|
| Price | $6.82 | $4.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $34.00 | $8.38 |
| AVG Volume (30 Days) | ★ 166.1K | 2.1K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,797,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.60 | $3.36 |
| 52 Week High | $14.56 | $5.36 |
Technical Indicators
Market Signals| Indicator | RNAC | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 53.70 |
| Support Level | $6.54 | $4.04 |
| Resistance Level | $7.81 | $4.50 |
| Average True Range (ATR) | 0.45 | 0.13 |
| MACD | 0.12 | 0.05 |
| Stochastic Oscillator | 57.01 | 81.16 |
Price Performance
Historical ComparisonAbout RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.